SCHEMBL5459965

SCHEMBL5459965

NC(=O)c1c(NC(=O)Nc2ccncc2)sc2cc(O)ccc12

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.45
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
TAAR1 Q96RJ0 2/20 0.41
DYRK1A Q13627 4/20 0.41
DYRK1B Q9Y463 2/20 0.41
BCHE P06276 2/20 0.40
LMNA P02545 1/20 0.40
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRIK1 P39086 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451109 0.88 MEN1 (0.56) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5453364 0.86 MEN1 (0.48) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5447596 0.86 GAA (0.48) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5456326 0.86 MEN1 (0.43) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5458283 0.86 MEN1 (0.43) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5455862 0.85 BAZ1A (0.51) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5455604 0.83 MAPT (0.48) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5460392 0.83 RAB9A (0.49) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL17625474 0.83 CA12 (0.43) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL5459689 0.82 MEN1 (0.50) KMT2AMEN1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MDM2 4821/4885KMT2A 4785/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.